CEACAM5 and rectal cancer: A recent study by Probst et al [21] demonstrated that rectal cancer patients with elevated pretreatment CEA are less likely to experience pCR, pathological tumor regression and downstaging, suggesting that these patients may not be suitable for “watch-and-wait” strategy.